Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-03-12

Clinical Trial Update: Enzalutamide in Patients With High-risk Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of enzalutamide in high-risk prostate cancer completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Enzalutamide (enzalutamide)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Adenocarcinoma of the Prostate | Phase 2 | Status: COMPLETED | Results posted: 2019-03-12